Monitor the conversion price and any subsequent dilution disclosures. The 10% discount suggests distressed terms; watch for further draws on the $10M facility and any impact on share price.
Price Chart
Executive Summary
Clearmind Medicine issued a notice to CLA Investors to sell $2,000,000 in convertible promissory notes at a 10% discount (net proceeds $1,800,000), expected to close by October 19, 2026. This is a dilutive financing event for a pre-revenue biotech, increasing debt and potential equity dilution.
Key Facts
- Company delivered notice on October 16, 2026 to issue $2,000,000 in convertible promissory notes to CLA Investors.
- Purchase price is 90% of principal, or $1,800,000 in cash.
- Transaction expected to close on or before October 19, 2026.
- Notes are part of an aggregate $10,000,000 facility under SPAs dated September 17, 2025, as amended April 30, 2026.
Financial Impact
Dilutive financing of $2,000,000 principal at 90% of par, netting $1,800,000 cash. Conversion terms not disclosed, but convertible notes typically dilute existing shareholders upon conversion.
Risk Factors
- Significant dilution risk upon conversion of promissory notes.
- Company is pre-revenue with no disclosed pipeline catalysts; reliance on dilutive financing raises going-concern risk.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-110220 |
| Document: 0001213900-26-110220-index-headers.html | 0001213900-26-110220 |
| Document: 0001213900-26-110220-index.html | 0001213900-26-110220 |
| Document: 0001213900-26-110220.txt | 0001213900-26-110220 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers